Open Access Open Access  Restricted Access Subscription or Fee Access

Abuse-deterrent formulations of opioids: Many questions still to answer

Raeford E. Brown Jr, MD, FAAP

Abstract


-

Full Text:

PDF

References


Jones CM, Mack KA, Paulozzi LJ: Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013; 309: 657-659.

FDA: Abuse deterrent opioids-evaluation and labeling guidance for industry. In: US Department of Health and Human Services, F.A.D.A., Center for Drug Evaluation and Research (CDER) (ed.) (2015).

Katz N, et al.: Tampering with prescription opioids: Nature and extent of the problem, health consequences, and solutions. AM. J. Drug Alcohol Abuse. 2011; 37: 205-217.

Cicero TJ, Ellis MS: Abuse deterrent formulations and the prescription opioid epidemic in the United States: Lessons learned from Oxycontin. JAMA Psychiatry. 2015; (72) 5: 424-430.

Jacobs, Harrison: There is a big problem with the government's plan to stop the drug overdose epidemic. Available at www. Business Insider.Com. Accessed March 14, 2016.

Grover, Natalie: Pfizer's opioid painkiller can be manipulated for abuse: FDA. Reuter's Business News, June 6, 2016.

Perrone, Matthew, et al.: Drugmakers push unproven solutions to opioid epidemic. KQED, Associated Press and Center for Public Integrity, December 20, 2016.

Anonymous. How to inject those waxy pain pills. The blue light Website, January 2017.

Cabral-Isabedra, Catherine: Oxycodone can still be extracted from Pfizer's painkillers. Tech Times, June 2016.

Mcanich, Jana: Review of Postmarketing Epidemiologic Data on Opana ER and Selected Comparators. Report to the FDA Advisory Committee on Anesthetic and Analgesic Drug Products and the Committee on Drug Safety and Risk Management, Silver Spring, MD. March 14, 2014.




DOI: http://dx.doi.org/10.5055/jom.2017.0402

Refbacks

  • There are currently no refbacks.